January 10, 2023 01:57 PM EST

FDA puts Vertex’s new Type 1 diabetes cell therapy IND on hold; Insilico sets up for PhII of AI drug

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Briefly mentioned in Vertex Pharmaceuticals’ JPM presentation Monday, the FDA has put an IND for Vertex’s new Type 1 diabetes cell therapy, VX-264, on hold …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA puts Vertex’s new Type 1 diabetes cell therapy IND on hold; Insilico sets up for PhII of AI drug

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Sofinnova outlines $550M fund after IPOs and M&A deals

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

FDA puts Ver­tex’s new Type 1 di­a­betes cell ther­a­py IND on hold; In­sil­i­co sets up for PhII of AI drug

News Reporter

Senior Reporter

Sign up to read this article for free.

more like this

FDA puts Vertex’s new Type 1 diabetes cell therapy IND on hold; Insilico sets up for PhII of AI drug